PROGNOSTIC VALUE OF CYP3A4*1B POLYMORPHISM IN PATIENTS WITH PULMONARY TUBERCULOSIS
DOI:
https://doi.org/10.32782/2226-2008-2024-1-7Keywords:
CYP3A4, tuberculosis, rifampicin, genotype, polymorphismAbstract
Introduction. Previously it was found that in slow metabolizers according to CYP3A4*1G genotype after completion of in-patient stage of anti-tuberculosis treatment, the level of cytolysis and toxicity indexes was much higher than in rapid metabolizers. The aim of the present research was to find the meaning of CYP3A4*1В polymorphism in tuberculosis (TB) patients for the level of isoniazid and rifampicin as well as for the outcome and toxicity development during in-patient TB treatment. Materials and methods. The medical records of 105 patients with pulmonary tuberculosis were examined. All these patients had primary pulmonary tuberculosis. They were receiving in-patient treatment at the Odesa Regional Center for Socially Significant Diseases (previously – the Odesa Regional Tuberculosis Dispensary) in 2012–2014. The study was conducted under the Declaration of Helsinki standards. Results. After in-patient treatment, the activity of cytolysis markers as alanine aminotransferase (ALT) and aspartate aminotransferase (AST), and the cholestasis marker as gamma-glutathione transferase (GGT) in TB-patients with *AA genotype increased insignificantly by 7.0%, 9.3%, and 4.5% (p>0.05); in patients with the *AG genotype, the activity of ALT, AST and GGT, on the contrary, had a tendency for decreasing – by 18.7%, 3.0% and 9.0% (p>0.05); a similar trend was observed concerning the number of patients with increased activity of ALT, AST and GGT. At the end of treatment, the average activity of ALT in carriers of the *AA genotype was 1.8 times higher than in carriers of the *AG genotype (p=0.046; CI=-0.26...22.24). Conclusion. At the beginning of anti-tuberculosis chemotherapy, it is recommended to determine the CYP3A4*1B genotype in patients with pulmonary tuberculosis, which allow identifying the groups of patients with the *AG genotype, which is characterized by a greater risk of developing sub-therapeutic rifampicin concentrations in the blood during treatment and prove the usefulness of personalized choice of rifampicin dosage according to the CYP3A4*1B genotype.
References
WHO. Global Tuberculosis Report 2021. Geneva: WHO. 2021, 43 p. Available from: https://apps.who.int/iris/rest/bitstreams/1379788/retrieve.
Butov D, Feshchenko Y, Chesov D, Myasoedov V. et al. National survey on the impact of the war in Ukraine on TB diagnostics and treatment services in 2022. International Journal of Tuberculosis and Lung Disease. 2023; 27(1):86–88. doi: https://doi.org/10.5588/ijtld.22.0563.
Chesnokova ММ, Bazhora YuІ, Antonenko KО, Ostapchuk KV. The pecularities of tuberculosis, caused by Beijing strains. Odesa Medical Journal. 2022; 1–2:55–59. doi: https://doi.org/10.54229/2226-2008-2022-1-2-10.
Antonenko PB, Kresyun VI, Antonenko KO. Mutations leading to drug-resistant Mycobacterium tuberculosis infection in Ukraine. Central European Journal of Medicine. 2010; 5(1): 30–35. doi: https://doi.org/10.2478/s11536-009-0114-6
Habibzadeh S, Shahi JM, Ghobadi H, Maleki N. The first report of two cases of fatal liver injury due to anti-tuberculosis drugs in the presence of alpha-1 antitrypsin deficiency. Int J Mycobacteriol. 2017; 6:187–90. doi: https://doi.org/10.4103/ijmy.ijmy_60_17.
Grankina NV, Lytvynenko NA. 8-months chemotherapy intensive phase in treatment of MDR-TB patients: is it really necessary? Ukr. Pulmonol. J. 2016; 2:29–31. Available from: http://www.ifp.kiev.ua/doc/journals/upj/16/pdf16-2/29.pdf (in Ukrainian).
Todoriko LD, Antonenko PB, Kuzhko MM, Semianiv IO, Tlustova TV. Influence of GSTM1 and NAT2 deletion polymorphism on efficiency of TB reatment and selection of way of administration of anti-TB reparations. Infusion & Chemotherapy. 2019; (1):9–16. https://doi.org/10.32902/2663-0338-2019-19-1-9-16 .
Antonenko PB. Influence of polymorphism of drug biotransformation processes on the effectiveness of anti-tuberculosis chemotherapy in humans. Doctor of Medicine dissertation: 14.01.28. Odesa National Medical University. 2015. 345 p. (in Ukrainian).
Antonenko P, Butov D, Kresyun V, Antonenko K, Butova T. Association between effectiveness of tuberculosis treatment and cytochrome P‑4502E1 polymorphism of the patients. Journal of Mycobacteriology. 2017; 6(4):396–400. doi: https://doi.org/10.4103/ijmy.ijmy_168_17.
Guttman Yelena, Nudel Adi, Kerem Zohar. Polymorphism in Cytochrome P450 3A4 Is Ethnicity Related. Front. Genet. 2019; 10:224;1–6. doi: https://doi.org/10.3389/fgene.2019.00224.
Francisco Blanco, Clemente Muriel, Jorge Labrador, Jose R. Gonzalez-Porras, Rogelio Gonzalez-Sarmiento, Francisco S. Lozano. Influence of UGT2B7, CYP3A4, and OPRM1 Gene Polymorphisms on Transdermal Buprenorphine Pain Control in Patients with Critical Lower Limb Ischemia Awaiting Revascularization. Pain Pract. 2015; 16(7):842–849. https://doi.org/10.1111/papr.12343.
Poludenko HO, Antonenko PB, Antonenko KO, Makarenko OV. Polymorphism of CYP3A4*1G gene as a predictor of the hepatotoxicity of antituberculosis therapy. Medicni Perspektivi. 2022; 27(1):97–103. https://doi.org/10.26641/2307-0404.2022.1.254369.
Loıc Le Marchand, Timothy Donlon, Laurence N. Kolonel, Brian E. Henderson, et al. Estrogen Metabolism-Related Genes and Breast Cancer Risk: The Multiethnic Cohort Study. Estrogen Cancer Epidemiol Biomarkers Prev. 2005; 14(8):1998–2003. doi: 10.1158/1055-9965.EPI-05-0076.
Dally H, Edler L, Jäger B, Schmezer P, Spiegelhalder B, Dienemann H, Drings P, Schulz V, Kayser K, Bartsch H, Risch A. The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose. Pharmacogenetics. 2003 Oct; 13(10):607–18. doi: 10.1097/00008571-200310000-00004.
Amirimani B, Ning B, Deitz AC, Weber BL, Kadlubar FF, Rebbeck TR. Increased transcriptional activity of the CYP3A4*1B promoter variant. Environ Mol Mutagen. 2003; 42(4):299–305. doi: 10.1002/em.10199.
